Journal of Neural Transmission

, Volume 126, Issue 1, pp 19–25 | Cite as

Genetic variations in the ADCK1 gene predict paliperidone palmitate efficacy in Han Chinese patients with schizophrenia

  • Yun-Ai Su
  • Chad Bousman
  • Qian Li
  • Ji-Tao Li
  • Jing-Yu Lin
  • Tian-Mei SiEmail author
Psychiatry and Preclinical Psychiatric Studies - Original Article


Genome-wide association study results have linked ADCK1 genetic variation with paliperidone efficacy in a European cohort. However, the generalizability of this locus to non-European populations is unknown. Han Chinese schizophrenia patients (n = 159) were treated with paliperidone palmitate and symptom severity was assessed over 3 months. Examination of 13 ADCK1 genetic variants revealed two single nucleotide polymorphisms (rs12590199, rs11159291) and one haplotype (rs2364747–rs12590199) associated with paliperidone palmitate response. Future work into ADCK1’s function and its potential interaction with paliperidone is warranted.


Schizophrenia Paliperidone palmitate ADCK1 Pharmacogenetics 



This research was supported by the National Natural Science Foundation of China (Nos. 81630031, 81571312), Capital Medical Development Research Fund (2016-1-4111), Beijing Municipal Science and Technology Project (Z171100000117016) and National Key Technology R&D Program (2015BAI13B01).

Supplementary material

702_2018_1953_MOESM1_ESM.docx (941 kb)
Supplementary material 1 (DOCX 942 KB)


  1. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, Karczewski KJ, Park J, Hitz BC, Weng S, Cherry JM, Snyder M (2012) Annotation of functional variation in personal genomes using RegulomeDB. Genome Res 22(9):1790–1797. CrossRefGoogle Scholar
  2. Brandl EJ, Kennedy JL, Muller DJ (2014) Pharmacogenetics of antipsychotics. Can J Psychiatry 59(2):76–88. CrossRefGoogle Scholar
  3. Consortium GT (2013) The Genotype-tissue expression (GTEx) project. Nat Genet 45(6):580–585. CrossRefGoogle Scholar
  4. Hough D, Lindenmayer JP, Gopal S, Melkote R, Lim P, Herben V, Yuen E, Eerdekens M (2009) Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 33(6):1022–1031. CrossRefGoogle Scholar
  5. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M (2007) Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 90(1–3):147–161. CrossRefGoogle Scholar
  6. Li Q, Wineinger NE, Fu DJ, Libiger O, Alphs L, Savitz A, Gopal S, Cohen N, Schork NJ (2017) Genome-wide association study of paliperidone efficacy. Pharmacogenet Genom 27(1):7–18. CrossRefGoogle Scholar
  7. Marder SR, Davis JM, Chouinard G (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58(12):538–546CrossRefGoogle Scholar
  8. Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A (2007) Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 62(12):1363–1370. pii].CrossRefGoogle Scholar
  9. Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, Eerdekens M (2008) Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 69(5):817–829CrossRefGoogle Scholar
  10. Mi W, Liu F, Liu Y, Du B, Xiao W, Li L, Huang L, Lu T, He J, Shi L, Yue W, Zhang H (2016) Association of ABCB1 gene polymorphisms with efficacy and adverse reaction to risperidone or paliperidone in han chinese schizophrenic patients. Neurosci Bull 32 (6):547–549. CrossRefGoogle Scholar
  11. Narum SR (2006) Beyond bonferroni: less conservative analyses for conservation genetics. Conserv Genet 7(5):783–787CrossRefGoogle Scholar
  12. Pouget JG, Shams TA, Tiwari AK, Muller DJ (2014) Pharmacogenetics and outcome with antipsychotic drugs. Dialogues Clin Neurosci 16(4):555–566Google Scholar
  13. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81(3):559–575. CrossRefGoogle Scholar
  14. Wang D, Fu DJ, Wu X, Shapiro A, Favis R, Savitz A, Chung H, Alphs L, Gopal S, Haas M, Cohen N, Li Q (2015) Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment response in patients with schizophrenia. Pharmacogenet Genom 25(4):173–185. CrossRefGoogle Scholar
  15. Zhang JP, Malhotra AK (2011) Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol 7(1):9–37. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2018

Authors and Affiliations

  • Yun-Ai Su
    • 1
  • Chad Bousman
    • 2
  • Qian Li
    • 1
  • Ji-Tao Li
    • 1
  • Jing-Yu Lin
    • 1
  • Tian-Mei Si
    • 1
    Email author
  1. 1.Peking University Sixth Hospital and Peking University Institute of Mental Health and Key Laboratory of Mental Health, Ministry of Health (Peking University) and National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital)BeijingChina
  2. 2.Departments of Medical Genetics, Psychiatry, and Physiology and PharmacologyUniversity of CalgaryCalgaryCanada

Personalised recommendations